Development of discriminating method for dissolution of aceclofenac marketed formulations

Dissolution Technologies

Volumn 15, Issue 2, 2008, Pages 31-35

  Soni, Tejal ^a   Nagda, Chirag ^b   Gandhi, Tejal ^b   Chotai, N P ^c  

^a ANAND PHARMACY COLLEGE   (India)

^b Indukaka College of Pharmacy   (India)

^c AR Patel and GH Patel Institute of Pharmacy   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATE BUFFERED SALINE; SURFACTANT;

ARTICLE; DISSOLUTION; DRUG FORMULATION; DRUG INDUSTRY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; PH;

EID: 70350661431     PISSN: 1521298X     EISSN: None     Source Type: Journal    
DOI: 10.14227/DT150208P31     Document Type: Article

References (22)

1. Dressman, J. B.; Amidon, G. L.; Reppas, C.; Shah, V. P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 1998, 15, 11-22.
2. Pillay, V.; Fassihi, R. Evaluation and comparison of dissolution data derived from different modified release dosage forms: an alternative method. J. Controlled Release 1998, 55, 45-55.
3. SUPAC-MR: Modified Release Solid Oral Dosage Forms. Scale-Up and Post Approval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation; Guidance for Industry; U.S. Department of Health and Human Services, Food and Drug Administration, U.S. Government Printing Office: Washington, DC, 1997.
4. Shah, V. P.; Konecny, J. J.; Everett, R. L.; McCullough, B.; Noorizadeh, A. C.; Skelly, J. P. In vitro dissolution profile of water-insoluble drug dosage forms in the presence of surfactants. Pharm. Res. 1989, 6 (7), 612-618.
5. Carstensen, J. T. Physico-chemical aspects of drug release. In Formulation and Preparation of Dosage Forms, Proceedings of the 37th International Congress of Pharmaceutical Sciences of F.I.P., The Hague, Netherlands, Sept 5-9, 1977; Polderman, J., Ed.; Elsevier: Amsterdam; 1977.
6. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12, 413-420.
7. Jinno, J.; Oh, D.; Crison, J. R.; Amidon, G. L. Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. J. Pharm. Sci. 2000, 89 (2), 268-274.
8. Jamzad, S.; Fassihi, R. Role of Surfactant and pH on Dissolution Properties of Fenofibrate and Glipizide-A Technical Note. AAPS PharmSciTech 2006, 7 (2), Article 33. http://www.aapspharmscitech.org/view.asp?art=pt070233 (accessed April 7, 2008).
9. Balakrishnan, A.; Rege, B. D.; Amidon, G. L.; Polli, J. E. Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity. J. Pharm. Sci. 2004, 93, 2064-2075.
10. Fortunato, D. Dissolution Method Development for Immediate Release Solid Oral Dosage Forms. Dissolution Technol. 2005, 12 (3), 12-15.
11. Brown, C.; Chokshi, H.; Nickerson, B.; Reed, R.; Rohrs, B.; Shah, P. Acceptable analytical practices for dissolution testing of poorly soluble compounds. Pharm. Technol. 2004, 28 (12), 56-65.
12. Noory, C.; Tran, N.; Ouderkirk, L.; Shah, V. Steps for Development of a Dissolution Test for Sparingly Water-Soluble Drug Products. Dissolution Technol. 2000, 7 (1), 16-18.
13. Siewert, M. FIP Guidelines for Dissolution Testing of Solid Oral Products. Pharm. Ind. 1995, 57, 362-369.
14. Shah, V. P. In Vitro Dissolution Profile of Water Insoluble Drug Dosage Forms in the Presence of Surfactants. Pharm. Res. 1989, 6, 612-618.
15. Dissolution Testing of Immediate Release Solid Oral Dosage Forms; Guidance for Industry; U.S. Department of Health and Human Services, Food and Drug Administration, U.S. Government Printing Office: Washington, DC, 1997.
16. International Pharmaceutical Federation (FIP) guidelines for dissolution testing of solid oral products. Drug Inf. J. 1996, 30, 1071-1084.
17. Moore, J. W.; Flanner, H. H. Mathematical comparison of dissolution profiles. Pharm. Technol. 1996, 20, 64-74.
18. Podczeck, F. Comparison of in vitro dissolution profiles by calculating mean dissolution time (MDT) or mean residence time (MRT). Int. J. Pharm. 1993, 97, 93-100.
19. Polli, J. E.; Rekhi, G. S.; Augsburger, L. L.; Shah, V. P. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. J. Pharm. Sci. 1997, 86, 690-700.
20. Shah, V. P.; Tsong, Y.; Sathe, P.; Williams, R. L. In Vitro Dissolution Profile Comparison-Statistics and Analysis of the Similarity Factor, f2. Pharm. Res. 1998, 15, 889-895.
21. Galia, E.; Nicolaides, E.; Horter, D.; Lobenberg, R.; Reppas, C.; Dressman, J. B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 1998, 15, 698-705.
22. Stella, V. J.; Martodihardjo, S.; Terada, K.; Venkatramana, M. R. Some relationships between the physical properties of various 3-acyloxymethyl prodrugs of phenytoin to structure: potential in vivo performance implication. J. Pharm. Sci. 1998, 87, 1235-1241